Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech Social Media Collaboration Will Focus On Patient Experiences In Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Under the five-year research collaboration, Genentech will have broad access to the online patient network PatientsLikeMe, which has 250,000 members.

You may also be interested in...



FDA Acquires Trove Of Rx Safety Data Through Alliance With PatientsLikeMe

Research collaboration will give FDA access to individual drug safety reports from patient network’s 350,000 members and could lead to future projects on post-market surveillance.

PatientsLikeMe Offering Rapid Patient Feedback On Clinical Trial Design

Global online patient network PatientsLikeMe launches a service to inform clinical trial development with retrospective data mining and prospective research using its online patient network.

Patient-Reported Outcomes Tools Should Be Symptom Specific, FDA Says

Agency favors symptom-focused assessments over global quality-of-life evaluations when considering whether the data can support a drug labeling claim for use in treating pediatric cancer. Measures used for EU reimbursement considerations are usually not sufficient for FDA labeling claims, official cautions.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel